Angeion Corporation to Present at the Roth Capital Partners 19th Annual OC Conference.

ST. PAUL, Minn. -- Angeion Corporation (NASDAQ:ANGN) today announced that Rodney Young, the Company's President and Chief Executive Officer, will be presenting at the Roth Capital Partners 19th Annual OC Conference, to be held February 19-22, 2007, at the Ritz Carlton in Laguna Niguel, California.

Angeion's investor presentation is scheduled for Wednesday, February 21, 2007 at 2:00 p.m. PT.

About Angeion Corporation

Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements by their nature involve substantial risks and uncertainties. Our results may differ materially depending on a variety of factors, including: (i) Our ability to successfully operate our business including our ability to develop, improve, and update our cardiorespiratory diagnostic products, (ii) Our ability to effectively manufacture and ship our products in anticipated required quantities to meet customer demands, (iii) Our ability to successfully defend the Company from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products, (iv) Our ability to protect our intellectual property, (v) Our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures, and (vi) Our dependence on third-party vendors. Additional information with respect to the risks and uncertainties faced by the Company may be found in, and any prior discussion is qualified in its entirety by, the other risk factors that are described from time to time in Angeion's Securities and Exchange Commission reports, including but not limited to the Annual Report on Form 10-KSB for the year ended October 31, 2006, and subsequently filed reports.